Michael Patrick Donovan Sells 6,033 Shares of AxoGen, Inc. (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) VP Michael Patrick Donovan sold 6,033 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $46,333.44. Following the transaction, the vice president now owns 37,992 shares in the company, valued at $291,778.56. The sale was disclosed in a document filed with the SEC, which is available at this link.

Michael Patrick Donovan also recently made the following trade(s):

• On Thursday, March 7th, Michael Patrick Donovan sold 36,310 shares of AxoGen stock. The stock was sold at an average price of $8.81, for a total value of $319,891.10.

AxoGen Stock Performance

Shares of AXGN opened at $7.77 on Thursday. The business has a 50-day moving average of $9.26 and a 200 day moving average of $7.03. AxoGen, Inc. has a fifty-two week low of $3.45 and a fifty-two week high of $10.83. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.89 and a quick ratio of 2.14.

Institutional Investors Weigh In On AxoGen

Several large investors have recently added to or reduced their stakes in the company. ArrowMark Colorado Holdings LLC increased its holdings in AxoGen by 7.2% in the 2nd quarter. ArrowMark Colorado Holdings LLC now owns 3,921,033 shares of the medical equipment provider’s stock worth $35,799,000 after acquiring an additional 263,422 shares during the last quarter. BlackRock Inc. increased its holdings in AxoGen by 3.7% in the 2nd quarter. BlackRock Inc. now owns 3,291,244 shares of the medical equipment provider’s stock worth $30,049,000 after acquiring an additional 118,764 shares during the last quarter. Vanguard Group Inc. increased its holdings in AxoGen by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,478,521 shares of the medical equipment provider’s stock worth $12,393,000 after acquiring an additional 56,536 shares during the last quarter. First Light Asset Management LLC increased its holdings in AxoGen by 6.0% in the 1st quarter. First Light Asset Management LLC now owns 2,423,335 shares of the medical equipment provider’s stock worth $19,241,000 after acquiring an additional 137,962 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in AxoGen by 12.1% in the 1st quarter. Bank of America Corp DE now owns 1,729,912 shares of the medical equipment provider’s stock worth $13,736,000 after acquiring an additional 187,205 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

AXGN has been the topic of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 target price on shares of AxoGen in a research note on Thursday, December 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 target price on shares of AxoGen in a research note on Friday, January 19th. Finally, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.